|
|
Volumn 22, Issue 2, 2016, Pages 116-119
|
|
An eye to the future: Researchers debate best path for stem cell-derived therapies
a
a
NONE
(United States)
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
AGE RELATED MACULAR DEGENERATION;
AUTOTRANSPLANTATION;
EMBRYONIC STEM CELL;
HEALTH CARE COST;
HUMAN;
HUMAN EMBRYONIC STEM CELL;
NOTE;
PATIENT SAFETY;
PLURIPOTENT STEM CELL;
PRIORITY JOURNAL;
RETINA CELL;
RETINA PIGMENT CELL;
RISK ASSESSMENT;
SOMATIC MUTATION;
STEM CELL RESEARCH;
STEM CELL TRANSPLANTATION;
VISUAL ACUITY;
ADVERSE EFFECTS;
ALLOTRANSPLANTATION;
ART;
COST;
ECONOMICS;
INDUCED PLURIPOTENT STEM CELL;
MACULAR DEGENERATION;
MEDICAL RESEARCH;
METABOLISM;
MUTATION;
PROCEDURES;
TRANSPLANTATION;
BIOMEDICAL RESEARCH;
COSTS AND COST ANALYSIS;
HUMAN EMBRYONIC STEM CELLS;
HUMANS;
INDUCED PLURIPOTENT STEM CELLS;
MACULAR DEGENERATION;
MUTATION;
STEM CELL TRANSPLANTATION;
TRANSPLANTATION, AUTOLOGOUS;
TRANSPLANTATION, HOMOLOGOUS;
|
|
EID: 84957592851
PISSN: 10788956
EISSN: 1546170X
Source Type: Journal
DOI: 10.1038/nm0216-116 Document Type: Note |
|
Times cited : (46)
|
|
References (0)
|
